This year’s eyeforpharma Barcelona conference might have seemed all doom and gloom at the outset, with many predicting the downfall of pharma as we know it – but there were plenty of speake
As part of pharmaphorum’s eye-on-innovation series of interviews, Richard Staines speaks to Michael Sierra, Vice President of LEO Pharma’s Science and Tech Hub, about how the firm plans to chan
Armed with new phase 3 data, Bayer has started preparing filings for elinzanetant as a treatment for vasomotor symptoms (VMS) associated with menopause, setting up a chall
The UK is welcoming a new era of clinical trial delivery, evolving beyond the traditional site-centric approach to also embrace remote, decentralised, virtual, and hybrid trials and enablin